Skip to Content

New Anti-Viral Drug Induces Significant Decrease in HBsAg in Hepatitis B

In this MEDtalk, Geoffrey Dusheiko, Kings College Hospital, and University College London, presents a new anti-viral drug class that may act as a new proxy for treatment and better classification of HBV patients. He also discussed the latest approaches to treating and managing HBV in this MEDtalk.

Geoffrey Dusheiko

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top